Giant cells lepromatous leprosy. Diffuse dermatitis with exuberant foreign body giant cells in treated lepromatous leprosy

Gerzaín Rodríguez, Viviana Arias, .

Keywords: Leprosy, leprosy, multibacillary, leprosy, lepromatous, drug therapy, combination

Abstract

Patients with lepromatous leprosy that have received treatment for many years usually get follow up biopsies for persistent skin lesions or positive bacilloscopy even if the values are lower than in the initial bacilloscopy.
We report the case of a 48-year old woman with long-standing lepromatous leprosy of 15 years of evolution, with a bacterial index of 4 in the direct smear and the initial skin biopsy.
The patient was treated with multidrug therapy for 32 months although the treatment recommended by the World Health Organization (WHO) is only for 12 months.
A skin biopsy was taken to determine if there was an active disease. We observed a diffuse dermal inflammation with numerous foreign body giant cells and vacuolated macrophages (Virchow´s cells). These cells contained granular acid-fast material that was also positive with immunohistochemistry for BCG. There were fragmented bacilli and the BI was 2.
These cells were also strongly positive for CD68. The biopsy was interpreted as a residual form of lepromatous leprosy that did not require further multidrug therapy.
We have observed similar histological profiles in several cases. The lack of clinical data makes it a histological challenge. The accumulation of lipids in these giant cells is due to bacillary destruction and fusion of vacuolated macrophages. We discuss here the role of bacillary and host lipids in the pathogenesis of lepromatous leprosy. We concluded that there was no need to extend the 12-month multidrug therapy recommended by WHO.

Downloads

Download data is not yet available.
  • Gerzaín Rodríguez Facultad de Medicina, Universidad de La Sabana, Chía, Colombia; Hospital Centro Dermatológico Federico Lleras Acosta, Bogotá, D.C., Colombia
  • Viviana Arias Departamento de Patología, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia http://orcid.org/0000-0001-6066-1271

References

Rodríguez G, Pinto R. La lepra. Imágenes y conceptos. Medellín: Universidad de Antioquia y Universidad de La Sabana; 2007. p. 128-36.

McDougall AC. Recent developments in the chemotherapy of leprosy. Lepr Rev. 1997;68:194-9.

Molina-Ruiz AM, Cerroni L, Kutzner H, Requena L. Immunohistochemistry in the diagnosis of cutaneous bacterial infections. Am J Dermatopathol. 2015;37:179-216. https://doi.org/10.1097/DAD.0000000000000227

Scollard DM. Pathogenesis and pathology of leprosy. Accessed: September 29, 2017. Available from: https://www.internationaltextbookofleprosy.org/sites/default/files/ITL_2_4%20FINAL_0.pdf

Kaur G, Kaur J. Multifaceted role of lipids in Mycobacterium leprae. Future Microbiol. 2017;12:315-35. https://doi.org/10.2217/fmb-2016-0173

Mattos KA, Sarno EN, Pessolani MCV, Bozza PT. Deciphering the contribution of lipid droplets in leprosy: Multifunctional organelles with roles in Mycobacterium leprae pathogenesis. Mem Inst Oswaldo Cruz. 2012;107(Suppl.1):156-66. https://doi.org/10.1590/S0074-02762012000900023

Guenin-Macé L, Simeone R, Demangel C. Lipids of pathogenic mycobacteria: Contributions to virulence and host immune suppression. Transbound Emerg Dis. 2009;56:255-68. https://doi.org/10.1111/j.1865-1682.2009.01072.x

Cruz D, Watson AD, Miller CS, Montoya D, Ochoa M-T, Sieling PA, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008;118:2917-28. https://doi.org/10.1172/JCI34189

Degang Y, Akama T, Hara T, Tanigawa K, Ishido Y, Gidoh M, et al. Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages. PLoS Negl Trop Dis. 2012;6:e1936. https://doi.org/10.1371/journal.pntd.0001936

Ridley DS. Skin biopsy in leprosy. Second edition. Basle: Documenta Geigy; 1995. p. 112-21.

Majno G, Joris I. Symptoms of cellular disease: Intracellular accumulations. In: Majno G, Joris I, editors. Cells, tissues and disease. Second edition. New York: Oxford Academic Press; 2004. p. 75-112.

Kumar A, Girdhar A, Girdhar BK. Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: Incidence of relapses in Agra field-based cohort study. Indian J Med Res. 2013;138:536-40.

Ebenezer GJ, Daniel S, Norman G, Daniel E, Job CK. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months’ and 24 months’ multi-drug therapy? Indian J Lepr. 2004;76:199-206.

How to Cite
1.
Rodríguez G, Arias V. Giant cells lepromatous leprosy. Diffuse dermatitis with exuberant foreign body giant cells in treated lepromatous leprosy. biomedica [Internet]. 2019 Aug. 1 [cited 2024 May 18];39(Supl. 2):26-31. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/4493

Some similar items:

Published
2019-08-01

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code